Elsevier signs agreement with Tunisian Ministry of Higher Education

Deal brings scientific and medical information to entire research community throughout Tunisia.

Amsterdam, 4 January 2005 - Elsevier announced the signing of a one-year agreement with the Ministry of Higher Education, Scientific Research and Technology in Tunisia for the provision of on-line access to vital scientific and medical information.

The agreement provides the entire research community throughout Tunisia - which is made up of over 9,200 researchers - with complete access to all journals available on Elsevier’s ScienceDirect. This agreement provides full-text articles from over 1,800 journals going back to 1999, and covering authoritative titles from core scientific and medical literature. High impact factor titles such as The Lancet and Tetrahedron will be covered by this agreement.

Elsevier was the first publisher the Ministry selected, following a trial period of access to all journals on ScienceDirect. The Tunisian research community quickly realized the value of having access to over 6 million full text articles, and the overall interest was overwhelming. The ministry selected 60 electronic subscriptions beginning in 2003, and increased that number to 200 over the course of 2004.

"We greatly appreciate access to Elsevier’s journal portfolio, and recognize the great value it brings to the Tunisian research community,” said Madam Ben Abdallah, Director, Centre National Universitaire de Documentation Scientifique et Technique (part of the Tunisian Ministry of Higher Education.)

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).